Cargando…

Sorafenib in advanced melanoma: a critical role for pharmacokinetics?

BACKGROUND: Inter-patient pharmacokinetic variability can lead to suboptimal drug exposure, and therefore might impact the efficacy of sorafenib. This study reports long-term pharmacokinetic monitoring of patients treated with sorafenib and a retrospective pharmacodynamic/pharmacokinetic analysis in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pécuchet, N, Lebbe, C, Mir, O, Billemont, B, Blanchet, B, Franck, N, Viguier, M, Coriat, R, Tod, M, Avril, M-F, Goldwasser, F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405224/ https://www.ncbi.nlm.nih.gov/pubmed/22767146 http://dx.doi.org/10.1038/bjc.2012.287

Ejemplares similares

Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma
por: Mir, Olivier, et al.
Publicado: (2012)

Reversible Decrease of Portal Venous Flow in Cirrhotic Patients: A Positive Side Effect of Sorafenib
por: Coriat, Romain, et al.
Publicado: (2011)

Early Sorafenib-Induced Toxicity Is Associated with Drug Exposure and UGTIA9 Genetic Polymorphism in Patients with Solid Tumors: A Preliminary Study
por: Boudou-Rouquette, Pascaline, et al.
Publicado: (2012)

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
por: Eisen, T, et al.
Publicado: (2006)

Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study
por: Mouriaux, F, et al.
Publicado: (2016)

Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies
por: Eisen, T, et al.
Publicado: (2011)

Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study
por: Coriat, Romain, et al.
Publicado: (2016)

First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma
por: Le Tourneau, C, et al.
Publicado: (2016)

Population Pharmacokinetic Modelling and Simulation to Determine the Optimal Dose of Nanoparticulated Sorafenib to the Reference Sorafenib
por: Huh, Ki-Young, et al.
Publicado: (2021)

A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas
por: Lee, J K, et al.
Publicado: (2013)

Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib
por: Hussaarts, Koen G. A. M., et al.
Publicado: (2020)

Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT
por: Handolias, D, et al.
Publicado: (2010)

Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma
por: Balakirouchenane, David, et al.
Publicado: (2020)

Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats
por: Karbownik, Agnieszka, et al.
Publicado: (2020)

Inaugural bone metastases in non-small cell lung cancer: a specific prognostic entity?
por: Deberne, Mélanie, et al.
Publicado: (2014)

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial
por: Bengala, C, et al.
Publicado: (2010)

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
por: Procopio, G, et al.
Publicado: (2011)

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma
por: Larkin, J M G, et al.
Publicado: (2010)

A Phase I Study of High-Dose Interleukin-2 With Sorafenib in Patients With Metastatic Renal Cell Carcinoma and Melanoma
por: Monk, Paul, et al.
Publicado: (2014)

Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non–small cell lung cancer
por: Okamoto, Isamu, et al.
Publicado: (2009)

VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib
por: Kuiper, J L, et al.
Publicado: (2012)

Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity
por: Lee, J-M, et al.
Publicado: (2010)

Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma
por: Hottinger, A F, et al.
Publicado: (2014)

Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients
por: Huillard, O, et al.
Publicado: (2013)

Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer
por: Dose-Schwarz, J, et al.
Publicado: (2010)

A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer
por: Desar, I M E, et al.
Publicado: (2010)

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial
por: Escudier, B, et al.
Publicado: (2014)

S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma
por: El-Khoueiry, A B, et al.
Publicado: (2014)

Pharmacokinetic Drug Interaction Study of Sorafenib and Morphine in Rats
por: Karbownik, Agnieszka, et al.
Publicado: (2021)

Pharmacokinetic Interactions between Canagliflozin and Sorafenib or Lenvatinib in Rats
por: Cui, Yanjun, et al.
Publicado: (2022)

Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom
por: Palmer, D H, et al.
Publicado: (2013)

Pharmacokinetic interaction between mitotane and etoposide in adrenal carcinoma: a pilot study
por: Jouinot, Anne, et al.
Publicado: (2018)

No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects
por: Huang, Funan, et al.
Publicado: (2017)

Pharmacokinetic Exposures Associated With Oral Administration of Sorafenib in Dogs With Spontaneous Tumors
por: Cawley, Jacob R., et al.
Publicado: (2022)

Sorafenib in Advanced Hepatocellular Carcinoma: A Nationwide Retrospective Study of Efficacy and Tolerability
por: Køstner, Anne Helene, et al.
Publicado: (2013)

A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma
por: Kefford, R F, et al.
Publicado: (2009)

A phase I and pharmacokinetic study of novel taxane BMS-188797 and cisplatin in patients with advanced solid tumours
por: du Bois, A, et al.
Publicado: (2006)

Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis
por: Procopio, G, et al.
Publicado: (2013)

Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer
por: Bazzola, L, et al.
Publicado: (2015)

The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism
por: Wang, Xianming, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hhf12ga8m54m7ot990vml0d1ub